Drugs / MEDI3250
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT00860067 | Mar → May 2009 | — | MedImmune LLC | Completed | Met primary |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT02269488 | Nov 2014 → Feb 2015 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02269475 | Oct 2014 → Apr 2015 | — | AstraZeneca | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI3250 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02269488 ↗ |
| Modality | Vaccine | “quadrivalent live attenuated influenza vaccine (Q/LAIV; MEDI3250)” NCT00860067 ↗ |
| Route | Intranasal | “the recommended dosage schedule for intranasal administration is 0.2 mL (0.1 mL per nostril)” NCT02269475 ↗ |